Enliven Therapeutics, Inc.
About Enliven Therapeutics, Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$103.7M
- Total assets
- $476.2M
- Market cap
- $2.1B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $119.7M
- Operating income
- -$119.7M
- Income tax
- $0
- Net income
- -$103.7M
- EPS (basic)
- $-1.83
- EPS (diluted)
- $-1.83
Balance sheet
- Total assets
- $476.2M
- Current assets
- $474.9M
- Total liabilities
- $16.6M
- Current liabilities
- $16.6M
- Shareholders’ equity
- $459.6M
Cash flow
- Operating cash flow
- -$70.3M
- Investing cash flow
- -$173.8M
- Financing cash flow
- $218.9M
- Net cash flow
- -$25.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.1B
- EPS (diluted)
- $-1.83
- Shares outstanding
- 62.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 24, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $103.7M.
- Trading 30% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Enliven Therapeutics, Inc..
Write a review
News about Enliven Therapeutics, Inc.
News & sentiment via Polygon.io
